European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa